SecBot SecBot
Insider Cluster (6 insiders) ·Filed May 15, 2026

KPTI

Karyopharm Therapeutics Inc.
NEUTRAL
Impact 2/10
Horizonweeks Processed5mo ago
Insider cluster: 6 insiders, $0.0M total
Actionable Insight • Neutral

These sales are trivial and routine, ignore them. The real risk for KPTI is the $400M shelf registration (200%+ dilution) and cash runway ending late Q3 2026. Watch for an equity offering or partnership announcement as the financing catalyst, not insider trading patterns.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.14
T+0 close · May 15, 2026 · via day close
Latest settled
−71.57%
T+60 · $2.03
Vs SPY
−76.42%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $7.14entry
  2. T+1 · 6mo ago +4.62%α +5.27% · $7.47
  3. T+5 · 6mo ago +25.63%α +24.01% · $8.97
  4. T+20 · 5mo ago +27.45%α +25.87% · $9.10
  5. T+60 · 3mo ago −71.57%α −76.42% · $2.03
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Six KPTI insiders, including CEO Richard Paulson, sold shares on May 14 (the same day as Q1 earnings), totaling $35,000 in open-market sales. The dollar value is 0.02% of the $185M market cap, well below the 0.1% materiality floor. This is a routine cluster timed to a blackout-window opening, not an informed bearish signal. Separately, a director received a $0 grant of 15,508 shares on May 21 as non-cash compensation.

Key Financial Metrics

Direction
selling
Total Value
$35.0K
Insiders
6

Key Facts

  • Six insiders, including the CEO and CFO, sold shares on May 14 at $9.50, totaling $35,000.
  • Sales represent 0.02% of $185M market cap, immaterial by all proportionality standards.
  • Director Barry Greene received a 15,508-share $0 grant on May 21 (non-cash compensation).
  • Sales occurred on earnings day (Q1 2026 results filed May 14), consistent with a blackout-window opening.

Financial Impact

Total insider sales of $35K, or ~0.02% of market cap; plus $0 non-cash grant

dilution

Risk Factors

  • $400M shelf registration filed May 4 creates massive potential dilution (~200% of current market cap).
  • Cash runway only extends into late Q3 2026, acute financing risk constrains the stock.
  • Phase 3 SENTRY myelofibrosis trial missed a co-primary endpoint, creating pipeline uncertainty.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-KPTI-1779826082813

US Market Status

Market Closed · Opens in 8h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 26, 2026